D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
D. Ross Camidge, MD, director, Thoracic Oncology Clinical Program, program director, Thoracic Oncology Clinical and Translational Research Fellowship, University of Colorado Denver, discusses MET as a secondary driver in lung cancer.
<<<
View more from the NSCLC Special Report
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More